Discovery, Optimization, and Preclinical Pharmacology of EP652, a METTL3 Inhibitor with Efficacy in Liquid and Solid Tumor Models.
Guillaume Dutheuil, Killian Oukoloff, Julien Korac...
https://pubmed.ncbi.nlm.nih.gov/39883878/Actively Recruiting
Led by Epics Therapeutics · Updated on 2026-06-11
48
Participants Needed
11
Research Sites
52 weeks
Total Duration
Researchers are evaluating EP102, an investigational drug, in participants with advanced solid tumors who have either no standard treatment options available or have not responded to existing therapies. This first-in-human Phase 1 study aims to determine the maximum tolerated dose MTD, safety, and how the drug behaves in the body, as well as an initial assessment of its effect on tumors. The study will help guide dosing for future research and treatment evaluations. Participants receive EP102 orally at different dose levels in a sequential, open-label design. The study focuses on identifying safe and tolerable doses, characterizing the drugs pharmacokinetic and pharmacodynamic profiles, and exploring anti-tumor activity. Treatment and assessments occur up to 21 days after the first dose, with continued evaluation until the study concludes. Throughout the trial, participants undergo evaluations to monitor safety, drug levels in the blood, and any effects on tumors. Researchers measure outcomes such as tolerability, pharmacokinetics, and tumor response. The study lasts up to the final completion date, with careful monitoring to inform the development of further studies and dosing strategies.
CONDITIONS
EP102 Safety and Efficacy in METTL3 Modulation in Advanced Solid Tumors
C
Clinical Trial Liaison
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Epics Therapeutics
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Up to 21 days after first administration
Participants receive oral EP102 at escalating dose levels to evaluate safety and determine the maximum tolerated dose.
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
5
Have more questions? Get in touch with our team for quick support
Guillaume Dutheuil, Killian Oukoloff, Julien Korac...
https://pubmed.ncbi.nlm.nih.gov/39883878/Lilia Abbad, Christos Chatziantoniou
https://pubmed.ncbi.nlm.nih.gov/42210870/Epics Therapeutics
Lead Sponsor